GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

GETI.B

213.1

0%↓

CAMX

606.5

-0.25%↓

BIOAB

321.4

+0.82%↑

EKTA.B

56.05

-0.09%↓

VITR

137.7

-0.22%↓

Home・Akciju saraksts・Vivesto AB

Vivesto AB

Slēgts

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	2.3M -7.2M
EPS	-0.013
Darbinieki	4
EBITDA	-7.1M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-5.5M 73M
Iepriekšējā atvēršanas cena	0
Iepriekšējā slēgšanas cena	0

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. dec. 21:41 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025. g. 26. dec. 20:22 UTC

Tirgus saruna

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025. g. 26. dec. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025. g. 26. dec. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025. g. 26. dec. 17:45 UTC

Tirgus saruna

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025. g. 26. dec. 15:52 UTC

Tirgus saruna

Oil Futures Turn Lower After Steady Start -- Market Talk

2025. g. 26. dec. 14:58 UTC

Tirgus saruna

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025. g. 26. dec. 14:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025. g. 26. dec. 14:28 UTC

Tirgus saruna

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025. g. 26. dec. 13:47 UTC

Tirgus saruna

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025. g. 26. dec. 07:22 UTC

Tirgus saruna

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025. g. 26. dec. 05:03 UTC

Tirgus saruna

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025. g. 26. dec. 01:39 UTC

Tirgus saruna

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025. g. 26. dec. 01:14 UTC

Tirgus saruna

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025. g. 26. dec. 00:34 UTC

Tirgus saruna

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025. g. 26. dec. 00:15 UTC

Tirgus saruna

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025. g. 25. dec. 23:42 UTC

Tirgus saruna

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025. g. 25. dec. 23:40 UTC

Tirgus saruna

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025. g. 25. dec. 00:20 UTC

Iegādes, apvienošanās, pārņemšana

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025. g. 24. dec. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025. g. 24. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025. g. 24. dec. 19:06 UTC

Tirgus saruna

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.